The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
EAHP’s SIG on Hospital Pharmacist’s Preparedness for in-vivo GTMP publishes report
Brussels, June 16. The first phase of the Special Interest Group on Hospital Pharmacist’s Preparedness for In-vivo Gene therapy medicinal products (GTMP) closed its work in April 2023. Since then, the SIG has been working on finalising the report that is being published today.
This report presents the findings of the Special Interest Group on Hospital Pharmacist’s Preparedness for GTMP. This SIG was financially supported by Pfizer and set up by the European Association of Hospital Pharmacists (EAHP).
The SIG carried out desk research and a survey to gather information on the hospital pharmacy preparedness for gene therapy medicines throughout Europe and on preparing and optimising multidisciplinary care teams for the integration of gene therapy medicines into the treatment tools for patients with rare diseases.
The report includes a proposal for future training activities on GTMP for hospital pharmacists and identifies the need for an update of the EAHP Guidance for Handling GTMP published in 2007. The SIG is currently working on the update on the Guidance.
For further information contact
info@eahp.eu | 00 322 669 2513
info@eahp.eu | 00 322 669 2513
1. The European Association of Hospital Pharmacists (EAHP) is a not-for-profit organisation that defends the interests of more than 25.000 European hospital pharmacists from its 36 full and associate member organisations. EAHP works to develop knowledge on hospital pharmacy to ease the improvement of care and outcomes for patients in the hospital setting. The Association achieves this through science, practice, research, education, as well as sharing best-practice and responsibility with other healthcare professionals. More information about EAHP is available HERE.
2. Read the report of EAHP’s SIG on the Hospital Pharmacy Preparedness for in vivo gene therapy medicinal products
https://eahp.eu/wp-content/uploads/2024/03/eahp_sig_gene_therapy_report.pdf
3. EAHP’s Special Interest Groups gather and evaluate the evidence in specific, innovative and novel fields of hospital pharmacy practice with the aim to address patient needs and to advance the profession. Learn more about EAHP’s SIGs HERE